Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy-Reference-Cited by-同舟云学术

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

Published:2015-12-01 Issue:9 Volume:1 Page:1340
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Lo Jennifer A.¹,Fisher David E.²,Flaherty Keith T.³

Affiliation:

1. Cutaneous Biology Research Center, Massachusetts General Hospital, Boston

2. Cutaneous Biology Research Center, Massachusetts General Hospital, Boston2Department of Dermatology, Massachusetts General Hospital, Boston3Massachusetts General Hospital Cancer Center, Boston

3. Massachusetts General Hospital Cancer Center, Boston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

2. Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center;Current Oncology;2024-02-19

3. Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis;Case Reports in Oncology;2024-01-05

4. Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features;Human Pathology;2023-10

5. Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction;Frontiers in Immunology;2023-06-22